Oramed Pharmaceuticals Inc. last reported quarterly results on Oct 24, 2025, for Q3 FY2025 (the quarter ended Sep 30, 2025): revenue of $2.0 million and diluted EPS of $1.13. It usually reports 24–41 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 24–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 24, 2025
24 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2
|
48
+346.7%
|
1.13
+335.4%
|
|
Nov 10, 2022
41 days after quarter end
|
—
ended Sep 30, 2022
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORMP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1176309
- Former names
- Integrated Security Technologies, Inc. (until Apr 10, 2006); IGUANA VENTURES LTD (until Jun 10, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.